Results 71 to 80 of about 1,283,944 (322)

Quantifying life: Understanding the history of Quality-Adjusted Life-Years (QALYs)

open access: yesSocial Science & Medicine, 2018
Quality-Adjusted Life-Years (QALYs) are central to healthcare decision-making in Britain and abroad, yet their history is poorly understood. In this paper, we argue that a more in-depth and political history of the QALY is needed to allow a critical evaluation of its current dominance.
Eleanor MacKillop, Sally Sheard
openaire   +3 more sources

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

open access: yesMolecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova   +18 more
wiley   +1 more source

ESTIMATING QALYS IN THE WESTERN REGION OF ROMANIA – THE CASE WITH INTERVENTION [PDF]

open access: yesAnnals of the University of Oradea: Economic Science, 2013
Currently, we are in the process of experimenting a diversification and refinement of the consumer’s expectations, as well as a growing demand for innovative, quality products and customized services, exacerbated by rapid technological change affecting
Pantea Marius, Gligor Delia, ,
doaj  

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review

open access: yesExpert Review of Vaccines, 2023
Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13.
Yuanze Du   +11 more
doaj   +1 more source

Determination of a cost-effectiveness threshold for cancer interventions in Iran

open access: yesFrontiers in Oncology, 2022
Background and objectivesThe estimation of a cost- Effectiveness (CE) threshold from the perspective of those who have experienced a life-threatening disease can provide empirical evidence for health policy makers to make the best allocation decisions on
Hossein Safari   +7 more
doaj   +1 more source

Cost-effectiveness of individualized nutrition and exercise therapy for rehabilitation following hip fracture [PDF]

open access: yes, 2016
OBJECTIVE: To undertake a cost-utility analysis of the Individual Nutrition Therapy and Exercise Regime: A Controlled Trial of Injured, Vulnerable Elderly (INTERACTIVE) trial. DESIGN: Cost-utility analysis of a randomized controlled trial.
Cameron, Ian D   +8 more
core   +2 more sources

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

Cost-effectiveness of proton beam therapy for intraocular melanoma. [PDF]

open access: yesPLoS ONE, 2015
Proton beam therapy is a commonly accepted treatment for intraocular melanomas, but the literature is lacking in descriptions of patient preferences of clinical outcomes and economic impact.
James P Moriarty   +4 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China

open access: yesFrontiers in Public Health, 2022
This study aimed to evaluate and compare nivolumab's cost-effectiveness with chemotherapy in patients with advanced esophageal squamous cell carcinoma from the Chinese healthcare system perspective.
Ying-tao Lin   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy